April 8, 2026
As biopharma licensing volumes reach unprecedented levels, disciplined valuation has never been more critical
The biopharma licensing landscape crossed a historic threshold in 2025. With over $250 billion in aggregate deal value spread across 516 transactions, the industry witnessed its most active year on record. For business development and licensing (BD&L) professionals, the implications are profound: in a market this competitive, the difference between a good deal and a great one often comes down to the rigour of the underlying valuation.
A Market Transformed by Volume and Velocity
Several converging forces have driven this licensing surge. Large pharmaceutical companies, facing patent cliffs projected to erode $180 billion to $400 billion in revenues between 2026 and 2030, are aggressively seeking external innovation to replenish pipelines. Simultaneously, a wave of clinical-stage biotechs, particularly from China, has flooded the market with licensable assets, reshaping the competitive dynamics of deal sourcing globally.
The result is a market where speed matters, but haste destroys value. BD teams that rely on back-of-the-envelope estimates or outdated comparables are increasingly outmanoeuvred by counterparts armed with rigorous, scenario-driven financial models.
Why Traditional Valuation Approaches Fall Short
In a record market, the temptation is to anchor to recent deal precedents. However, precedent-based valuation carries inherent risks when deal volumes and sizes are at historic highs. Comparable deals from even 12 months ago may reflect materially different risk-reward profiles, regulatory environments, and competitive landscapes.
Risk-adjusted net present value (rNPV) remains the gold standard for licensing valuations precisely because it forces discipline. By modelling probability-weighted cash flows across development stages, rNPV compels deal teams to articulate and defend every assumption — from probability of technical success (PTS) to peak sales estimates and royalty stacking considerations.
A Framework for Valuing Deals in a Surging Licensing Market
At Avance, our approach to deal valuation in this environment centres on three principles:
1. Scenario-Based Modelling Over Point Estimates
We build base, conservative, and optimistic scenarios for every asset, stress-testing key assumptions including market size, competitive entry timing, and pricing trajectory. In a seller’s market, buyers must understand not only the expected value but the full distribution of outcomes. This means that the full distribution shows the entire range of possible values and how likely each one is, based on uncertainty in trial success, market size, pricing, and competition. It matters because two assets with the same expected NPV can have very different risk profiles.
2. Benchmarking Against Live Data
Avance maintains proprietary databases of deal terms, royalty rates, and milestone structures drawn from over 250 completed advisory engagements. This allows us to benchmark proposed terms against genuine market conditions, rather than relying on publicly disclosed headline figures that often obscure the true economics.
3. Separating Strategic Value from Financial Value
Not every deal is purely financial. Platform partnerships, geographic access, and technology optionality carry strategic value that a pure DCF model cannot capture. Our methodology explicitly identifies and quantifies these strategic premia, ensuring that deal teams can negotiate from an informed position.
The Cost of Getting It Wrong
In a $250 billion market, overpaying by even a modest percentage translates into hundreds of millions in misallocated capital. Conversely, undervaluing a licensing opportunity means losing it to a better-prepared competitor. The stakes have never been higher.
For BD&L professionals, the imperative is clear: invest in valuation infrastructure — methodology, data, and technology — before entering negotiations. The firms that consistently win the best deals are those that arrive at the table with the most defensible numbers.
Conclusion
The $250 billion licensing surge is not an anomaly; it reflects structural shifts in how the biopharma industry sources and monetises innovation. In this environment, disciplined valuation is critical. Avance Life Sciences, with its industry-standard methodology, proprietary models and benchmarking and two decades of deal-making expertise, stands ready to help BD teams navigate this unprecedented market with confidence.